Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate long term safety, efficacy and tolerability of ABT-874 in adults with moderate to severe psoriasis.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
AbbVie (prior sponsor, Abbott)
NCT06888193 · Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, and more
NCT07234591 · Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
NCT06943950 · Moderate to Severe Plaque Psoriasis
NCT02982005 · Moderate to Severe Plaque Psoriasis
NCT02660580 · Psoriasis, Plaque Type Psoriasis, and more
Site Reference ID/Investigator# 7496
Birmingham, Alabama
Site Reference ID/Investigator# 8438
Birmingham, Alabama
Site Reference ID/Investigator# 7522
Huntsville, Alabama
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions